News

Tamoxifen, Raloxifene Upheld for Prevention


 

“The challenge today is how to communicate to the public to enhance the utilization of SERMs and reduce further the incidence of breast cancer,” he said.

Disclosures: The study was supported by the National Cancer Institute. Dr. Wickerham reported that he has consulted for Eli Lilly.

'These data are good news for postmenopausal women who want to reduce their risk of breast cancer.'

Source DR. WICKERHAM

'The challenge today is how to communicate to the public to enhance the utilization of SERMs.'

Source DR. HORTOBAGYI

Pages

Recommended Reading

Aspirin May Boost Survival After Breast Cancer
MDedge Family Medicine
Fetal Growth Restriction Tied To Smoking, Low Folic Acid
MDedge Family Medicine
Increased Foley Catheter Inflation May Aid Labor Induction
MDedge Family Medicine
Coffee May Reduce Endometrial Cancer Risk
MDedge Family Medicine
Data Don't Support Routine Bilateral Oophorectomy
MDedge Family Medicine
Guided Ultrasound Ablation Improves Fibroid Symptoms
MDedge Family Medicine
EC On Hand Failed to Cut Pregnancy Rates
MDedge Family Medicine
NAMS Revises Statement on Postmenopausal HT
MDedge Family Medicine
Treating UTIs in reproductive-age women—Proceed with caution
MDedge Family Medicine
Fever, cough, and hypoxia in a pregnant woman
MDedge Family Medicine